CALR mutations, characteristic of essential thrombocythemia and primary myelofibrosis, represent a significant group of MPN cases and, compared with other mutations such as JAK2 or MPL, show distinct clinical and prognostic features. This evidence concerns the gene CALR and myeloproliferative disorder.